000			03513nam a22006017a 4500
008			170428s20172017 xxu||||| |||| 00| 0 eng d
022			_a0902-0063
040			_aOvid MEDLINE(R)
099			_a28239909
245			_aLedipasvir/sofosbuvir is effective and well tolerated in postkidney transplant patients with chronic hepatitis C virus.
251			_aClinical Transplantation. 31(5), 2017 May
252			_aClin Transplant. 31(5), 2017 May
253			_aClinical transplantation
260			_c2017
260			_fFY2017
266			_d2017-05-06
520			_aCopyright (c) 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
520			_aPatients with end-stage renal diseases on hemodialysis have a high prevalence of hepatitis C infection (HCV). In most patients, treatment for HCV is delayed until postrenal transplant. We assessed the effectiveness and tolerance of ledipasvir/sofosbuvir (LDV/SOF) in 32 postkidney transplant patients infected with HCV. The group was composed predominantly of treatment-naive (75%) African American (68.75%) males (75%) infected with genotype 1a (62.5%). Most patients received a deceased donor kidney graft (78.1%). A 96% sustained viral response (SVR) was reported (27/28 patients). One patient relapsed. One patient with baseline graft dysfunction developed borderline rejection. No graft loss was reported. Six HIV-coinfected patients were included in our analysis. Five of these patients achieved SVR 12. There were four deaths, and one of the deaths was in the HIV group. None of the deaths were attributed to therapy. Coinfected patients tolerated therapy well with no serious adverse events. Serum creatinine remained stable at baseline, end of therapy, and last follow-up, (1.351+/-.50 mg/dL; 1.406+/-.63 mg/dL; 1.290+/-.39 mg/dL, respectively). In postkidney transplant patients with HCV infection with or without coinfection with HIV, a combination of LDV/SOF was well tolerated and effective.
546			_aEnglish
650			_a*Benzimidazoles/tu [Therapeutic Use]
650			_a*Coinfection/dt [Drug Therapy]
650			_a*Fluorenes/tu [Therapeutic Use]
650			_a*Hepacivirus/de [Drug Effects]
650			_a*Hepatitis C, Chronic/dt [Drug Therapy]
650			_a*Kidney Failure, Chronic/su [Surgery]
650			_a*Kidney Transplantation/ae [Adverse Effects]
650			_a*Postoperative Complications/dt [Drug Therapy]
650			_a*Uridine Monophosphate/aa [Analogs & Derivatives]
650			_aAntiviral Agents
650			_aFemale
650			_aFollow-Up Studies
650			_aGlomerular Filtration Rate
650			_aGraft Survival
650			_aHepacivirus/ge [Genetics]
650			_aHepatitis C, Chronic/vi [Virology]
650			_aHumans
650			_aImmunosuppressive Agents/tu [Therapeutic Use]
650			_aKidney Function Tests
650			_aMale
650			_aMiddle Aged
650			_aPostoperative Complications/vi [Virology]
650			_aPrognosis
650			_aRetrospective Studies
650			_aRisk Factors
650			_aUridine Monophosphate/tu [Therapeutic Use]
651			_aMedStar Washington Hospital Center
656			_aTransplant Hepatology
657			_aJournal Article
700			_aLalos, Alexander
790			_aHassan M, Lalos A, Liriano-Ward L, Morales AL, Nair V, Sang M, Satoskar R, Schiano T, Smith C, Tierney A
856			_uhttps://dx.doi.org/10.1111/ctr.12941 _zhttps://dx.doi.org/10.1111/ctr.12941
942			_cART _dArticle
999			_c3329 _d3329